AGTR1 and glioblastoma: miR-155 not only controls the expression of angiotensin II type 1 receptors but also attenuates angiogenesis and the angiotensin II type 1 receptor/CXCR4/NF-κB signaling pathway, promoting antitumor effects against glioblastoma cells [21].